Michael S Schechter

List of Publications by Year
in descending order

70 papers	2,138 citations	186265 28 h-index	243625 44 g-index
70 all docs	70 docs citations	70 times ranked	1966 citing authors

#	Article	IF	Citations
1	The National Spina Bifida Patient Registry: Profile of a Large Cohort ofÂParticipants from the First 10 Clinics. Journal of Pediatrics, 2015, 166, 444-450.e1.	1.8	117
2	Impact of Socioeconomic Status, Race, and Ethnicity on Quality of Life in Patients With Cystic Fibrosis in the United States. Chest, 2010, 137, 642-650.	0.8	110
3	Relationship between socioeconomic status and disease severity in cystic fibrosis. Journal of Pediatrics, 1998, 132, 260-264.	1.8	97
4	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 763-770.	2.0	94
5	Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis. Journal of Pediatrics, 2009, 155, 634-639.e4.	1.8	92
6	Design and Methodological Considerations of the Centers for Disease Control and Prevention Urologic and Renal Protocol for the Newborn and Young Child with Spina Bifida. Journal of Urology, 2016, 196, 1728-1734.	0.4	85
7	Risk factors for mortality before age 18 years in cystic fibrosis. Pediatric Pulmonology, 2017, 52, 909-915.	2.0	71
8	The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement. BMJ Quality and Safety, 2014, 23, i9-i14.	3.7	65
9	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. Journal of Pediatrics, 2015, 167, 1081-1088.e1.	1.8	63
10	Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function. Pediatrics, 2007, 119, e531-e537.	2.1	60
11	Sociodemographic Attributes and Spina Bifida Outcomes. Pediatrics, 2015, 135, e957-e964.	2.1	60
12	Improving Subspecialty Healthcare: Lessons from Cystic Fibrosis. Journal of Pediatrics, 2005, 147, 295-301.	1.8	59
13	Long-term Effects of Pregnancy and Motherhood on Disease Outcomes of Women with Cystic Fibrosis. Annals of the American Thoracic Society, 2013, 10, 213-219.	3.2	56
14	Nongenetic influences on cystic fibrosis outcomes. Current Opinion in Pulmonary Medicine, 2011, 17, 448-454.	2.6	55
15	Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project. BMJ Quality and Safety, 2014, 23, i15-i22.	3.7	54
16	Non-Genetic Influences on Cystic Fibrosis Lung Disease: The Role of Sociodemographic Characteristics, Environmental Exposures, and Healthcare Interventions. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 639-652.	2.1	49
17	Socioeconomic status and health outcomes: cystic fibrosis as a model. Expert Review of Respiratory Medicine, 2016, 10, 967-977.	2.5	49
18	Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms. Pediatric Pulmonology, 2013, 48, 649-657.	2.0	44

#	Article	IF	Citations
19	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatric Pulmonology, 2015, 50, 431-440.	2.0	43
20	Improving the quality of care for patients with cystic fibrosis. Current Opinion in Pediatrics, 2010, 22, 296-301.	2.0	40
21	Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatric Pulmonology, 2011, 46, 497-504.	2.0	39
22	Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. Annals of the American Thoracic Society, 2018, 15, 234-240.	3.2	37
23	Airway clearance applications in infants and children. Respiratory Care, 2007, 52, 1382-90; discussion 1390-1.	1.6	37
24	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. Journal of Pediatrics, 2011, 159, 819-824.e1.	1.8	36
25	Pancreatic Enzyme Replacement Therapy Dosing and Nutritional Outcomes in Children with Cystic Fibrosis. Journal of Pediatrics, 2014, 164, 1110-1115.e1.	1.8	36
26	Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States. Current Medical Research and Opinion, 2017, 33, 667-674.	1.9	32
27	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society, 2018, 15, 225-233.	3.2	32
28	Patient Registry Analyses: Seize the Data, but Caveat Lector. Journal of Pediatrics, 2008, 153, 733-735.	1.8	31
29	Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors. Journal of Cystic Fibrosis, 2021, 20, 49-54.	0.7	31
30	Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 769-778.	0.7	30
31	Decreased survival in cystic fibrosis patients with a positive screen for depression. Journal of Cystic Fibrosis, 2021, 20, 120-126.	0.7	29
32	Snoring: Investigations guidelines. Pediatric Pulmonology, 2004, 37, 172-174.	2.0	26
33	Benchmarking to improve the quality of cystic fibrosis care. Current Opinion in Pulmonary Medicine, 2012, 18, 596-601.	2.6	26
34	Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 783-790.	0.7	26
35	Early Childhood Risk Factors for Decreased FEV1at Age 6-7 Years in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, 150819115840007.	3.2	25
36	Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, 864-871.	3.2	22

#	Article	IF	Citations
37	Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. Journal of Cystic Fibrosis, 2022, 21, 777-783.	0.7	22
38	Readiness for transition and healthâ€care satisfaction in adolescents with complex medical conditions. Child: Care, Health and Development, 2019, 45, 463-471.	1.7	19
39	Rate of Uptake of Ivacaftor Use after FDA Approval among Patients Enrolled in the United States Cystic Fibrosis Foundation Patient Registry. Annals of the American Thoracic Society, 2015, 12, 150613194115008.	3.2	18
40	Variation in surgical management of neurogenic bowel among centers participating in National Spina Bifida Patient Registry. Journal of Pediatric Rehabilitation Medicine, 2017, 10, 303-312.	0.5	17
41	Bladder Reconstruction Rates Differ among Centers Participating in National Spina Bifida Patient Registry. Journal of Urology, 2018, 199, 268-273.	0.4	16
42	The association of area deprivation and state child health with respiratory outcomes of pediatric patients with cystic fibrosis in the United States. Pediatric Pulmonology, 2021, 56, 883-890.	2.0	16
43	Outcomes and Treatment of Chronic Methicillin-ResistantStaphylococcus aureusDiffers by Staphylococcal Cassette Chromosomemec(SCCmec) Type in Children With Cystic Fibrosis. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 225-231.	1.3	15
44	Predictors of pulmonary exacerbation treatment in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 407-414.	0.7	15
45	Relationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 520-526.	1.8	12
46	Non-genetic influences on CF lung disease: The role of sociodemographic characteristics, environmental exposures and healthcare interventions. Pediatric Pulmonology, 2004, 37, 82-85.	2.0	10
47	Does distance to a cystic fibrosis center impact health outcomes?. Pediatric Pulmonology, 2018, 53, 284-292.	2.0	10
48	Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis. Paediatric Respiratory Reviews, 2021, , .	1.8	10
49	Risk Factors for Quantity Not Sufficient Sweat Collection in Infants 3 Months or Younger. American Journal of Clinical Pathology, 2014, 142, 72-75.	0.7	9
50	Reevaluating approaches to cystic fibrosis pulmonary exacerbations. Pediatric Pulmonology, 2018, 53, S51-S63.	2.0	9
51	Social Inequities and Cystic Fibrosis Outcomes: We Can Do Better. Annals of the American Thoracic Society, 2021, 18, 215-217.	3.2	9
52	Improving inpatient cystic fibrosis pulmonary exacerbation care: two success stories. BMJ Quality and Safety, 2014, 23, i33-i41.	3.7	8
53	Rate and predictors of prescription of lumacaftor â€“ Ivacaftor in the 18â€¯months following approval in the United States. Journal of Cystic Fibrosis, 2018, 17, 742-746.	0.7	8
54	Engaging with the Richmond Community to Reduce Pediatric Asthma Disparities: Findings from a Communityâ€engaged Needs Assessment. American Journal of Community Psychology, 2020, 66, 222-231.	2.5	8

#	Article	IF	Citations
55	Inhaled Aztreonam Lysine versus Inhaled Tobramycin in Cystic Fibrosis. An Economic Evaluation. Annals of the American Thoracic Society, 2015, 12, 1030-1038.	3.2	7
56	Comparing cystic fibrosis outcomes across the pond. Thorax, 2015, 70, 203-204.	5.6	7
57	Evaluating Long-Term Benefits of Chronic Azithromycin. Furthering Our Quest for Precision Medicine. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 398-400.	5.6	7
58	School Nurses' Perspectives on Components of Asthma Programs to Address Pediatric Disparities. Journal of Pediatric Psychology, 2020, 45, 900-909.	2.1	6
59	Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies. Expert Review of Respiratory Medicine, 2022, 16, 637-650.	2.5	4
60	Identifying and Integrating Parent Priorities for Psychosocial Support Services in a Pediatric Cystic Fibrosis Clinic. Journal of Clinical Psychology in Medical Settings, 2019, 26, 235-241.	1.4	3
61	A community-based asthma program: Study design and methods of RVA Breathes. Contemporary Clinical Trials, 2020, 97, 106121.	1.8	3
62	Bone mineral density screening by DXA for people with cystic fibrosis: A registry analysis of patient and program factors influencing rates of screening. Journal of Cystic Fibrosis, 2022, 21, 784-791.	0.7	3
63	Origins of growth deficiencies in cystic fibrosis. Thorax, 2019, 74, 423-424.	5.6	2
64	Speaking of pandemics.... Journal of Cystic Fibrosis, 2021, 20, 564-565.	0.7	2
65	Adaptations to the RVA Breathes clinical trial due to the COVID-19 pandemic. Contemporary Clinical Trials Communications, 2021, 24, 100871.	1.1	2
66	Is It Acceptable to Assess Prenatal Smoking Risk to Infants without Considering Socioeconomic Status?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 965-966.	5.6	1
67	Rapid lung function decline in adults with early-stage cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2020, 19, 527-533.	0.7	1
68	A mindful yoga intervention for children with severe asthma: A pilot study. Complementary Therapies in Clinical Practice, 2020, 40, 101212.	1.7	1
69	Comparing effectiveness and outcomes in asthma and cystic fibrosis. Paediatric Respiratory Reviews, 2017, 24, 24-28.	1.8	0
70	Health Disparities. Respiratory Medicine, 2020, , 35-55.	0.1	0